The ADC binds TROP-2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor (SHR9265) that causes DNA damage and apoptosis. Topoisomerase I is the intracellular enzymatic target of the payload, not the binding target; killing is driven by TROP-2–mediated delivery, not by Topo I expression per se.